Navigation Links
Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
Date:2/3/2009

EMERYVILLE, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a quarterly royalty payment of approximately $1.5 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of Alzheimer's disease. Under an exclusive marketing agreement, NTI currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The company recently terminated development of its most advanced product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials for evaluation as a new drug to treat acute ischemic stroke. NTI has an early-stage development program for Alzheimer's disease and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug which has recently completed a Phase 3 trial for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies Announces Suspension of Viprinex Development
2. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
3. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
4. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
5. Neurobiological Technologies Sets Date for First Quarter Financial Results
6. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
7. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
8. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
10. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
11. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Dallas-Fort Worth, Texas (PRWEB) , ... September 20, 2017 , ... ... people, stem cell therapy succeeded after standard medicine failed. Many of these people had ... - Progress, Not Regression Free Download (pdf) , “Neil ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... a standard fume hood and a high-performance fume hood. Along with the advantages ... and applications for ductless vs. ducted hoods in the laboratory. , Attendees will ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... an biological outbreak is about to be eliminated, said Lyle Probst, President, CEO ... FireflyDX™ technologies different than other pathogen detection solutions, Probst said, “Sample ...
(Date:9/19/2017)... Austin, TX (PRWEB) , ... ... ... New York State Department of Financial Services (NYS DFS) cybersecurity ... all regulated banking, finance and insurance organizations operating in the state (“Covered ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):